CL2015002442A1 - Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd - Google Patents

Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Info

Publication number
CL2015002442A1
CL2015002442A1 CL2015002442A CL2015002442A CL2015002442A1 CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1 CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A CL2015002442 A CL 2015002442A CL 2015002442 A1 CL2015002442 A1 CL 2015002442A1
Authority
CL
Chile
Prior art keywords
treatment
thymphylosthetic
pi3kd
disorders related
pyrazolopyrimidine derivatives
Prior art date
Application number
CL2015002442A
Other languages
English (en)
Spanish (es)
Inventor
Wenqing Yao
Yun-Long Li
Wenyu Zhu
Song Mei
Joseph Glenn
Andrew P Combs
Eddy W Yue
Jr Thomas P Maduskuie
Richard B Sparks
Brent Douty
Chunhong He
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2015002442A1 publication Critical patent/CL2015002442A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2015002442A 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd CL2015002442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
CL2015002442A1 true CL2015002442A1 (es) 2016-02-05

Family

ID=50288319

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002442A CL2015002442A1 (es) 2013-03-01 2015-08-31 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd

Country Status (32)

Country Link
US (6) US9932341B2 (enExample)
EP (3) EP4233869A3 (enExample)
JP (5) JP6545106B2 (enExample)
KR (5) KR102298150B1 (enExample)
CN (2) CN105120871B (enExample)
AR (1) AR094964A1 (enExample)
AU (5) AU2014223257B2 (enExample)
BR (1) BR112015020941A2 (enExample)
CA (1) CA2901993C (enExample)
CL (1) CL2015002442A1 (enExample)
CR (1) CR20150472A (enExample)
CY (1) CY1122712T1 (enExample)
DK (1) DK2961410T3 (enExample)
EA (2) EA202192151A1 (enExample)
ES (2) ES2774436T3 (enExample)
HR (1) HRP20200263T1 (enExample)
HU (1) HUE047719T2 (enExample)
IL (6) IL301180A (enExample)
LT (1) LT2961410T (enExample)
MX (2) MX367713B (enExample)
MY (1) MY177875A (enExample)
PE (1) PE20151996A1 (enExample)
PH (3) PH12021552233A1 (enExample)
PL (1) PL2961410T3 (enExample)
PT (1) PT2961410T (enExample)
RS (1) RS59958B1 (enExample)
SG (3) SG10201707130UA (enExample)
SI (1) SI2961410T1 (enExample)
SM (1) SMT202000043T1 (enExample)
TW (5) TWI841376B (enExample)
UA (1) UA119641C2 (enExample)
WO (1) WO2014134426A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HUE050215T2 (hu) 2013-01-15 2020-11-30 Incyte Holdings Corp Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
MA39984B1 (fr) 2014-04-08 2020-12-31 Incyte Corp Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
SI3371190T1 (sl) 2015-11-06 2022-08-31 Incyte Corporation Heterociklične spojine kot inhibitorji PI3K gama
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
DK3679042T3 (da) * 2017-09-08 2023-05-01 Beigene Ltd Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
BR112020013788A2 (pt) * 2018-01-10 2020-12-01 Idorsia Pharmaceuticals Ltd composto, composição farmacêutica, uso de um composto, e, método de tratamento.
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
TW202241436A (zh) 2020-11-30 2022-11-01 美商英塞特公司 抗cd19抗體及帕薩昔布(parsaclisib)之組合療法
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
US20230190755A1 (en) 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of PI3K-delta inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
AR073651A1 (es) 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2010234360A1 (en) 2009-04-09 2011-09-29 Oncothyreon, Incorporated Methods and compositions of PI-3 kinase inhibitors for treating fibrosis
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
PT2470546E (pt) 2009-08-28 2013-10-14 Takeda Pharmaceutical Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
PH12017501538B1 (en) * 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
CN112469418A (zh) * 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
US11161838B2 (en) * 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

Also Published As

Publication number Publication date
PH12019501321B1 (en) 2020-10-12
US20190040067A1 (en) 2019-02-07
JP2025003975A (ja) 2025-01-14
SMT202000043T1 (it) 2020-03-13
CA2901993C (en) 2023-03-07
JP2021020914A (ja) 2021-02-18
IL283943A (en) 2021-07-29
WO2014134426A1 (en) 2014-09-04
PH12021552233A1 (en) 2022-07-18
TWI657090B (zh) 2019-04-21
AU2014223257A1 (en) 2015-09-24
US20140249132A1 (en) 2014-09-04
EP4233869A2 (en) 2023-08-30
EP2961410A1 (en) 2016-01-06
PH12015501920A1 (en) 2016-01-18
IL240784A0 (en) 2015-10-29
MX2019010422A (es) 2019-10-15
PT2961410T (pt) 2020-03-02
TWI687220B (zh) 2020-03-11
AU2022218495A1 (en) 2022-09-08
IL267853B (en) 2020-03-31
IL311666A (en) 2024-05-01
IL301180A (en) 2023-05-01
JP2019142941A (ja) 2019-08-29
JP6545106B2 (ja) 2019-07-17
AR094964A1 (es) 2015-09-09
JP7556010B2 (ja) 2024-09-25
KR20240152422A (ko) 2024-10-21
ES2774436T3 (es) 2020-07-21
SI2961410T1 (sl) 2020-03-31
IL283943B2 (en) 2023-08-01
PL2961410T3 (pl) 2020-05-18
TW202333734A (zh) 2023-09-01
LT2961410T (lt) 2020-02-10
TWI841376B (zh) 2024-05-01
MX367713B (es) 2019-09-03
SG10201912275YA (en) 2020-04-29
IL267853A (en) 2019-09-26
KR20210110409A (ko) 2021-09-07
BR112015020941A2 (pt) 2017-07-18
CN109010343A (zh) 2018-12-18
KR20150135327A (ko) 2015-12-02
US12152033B2 (en) 2024-11-26
TW202019428A (zh) 2020-06-01
EP3632442B1 (en) 2023-04-05
EA202192151A1 (ru) 2021-12-31
CA2901993A1 (en) 2014-09-04
HK1221398A1 (en) 2017-06-02
PE20151996A1 (es) 2016-01-13
UA119641C2 (uk) 2019-07-25
TW201929860A (zh) 2019-08-01
AU2018264053A1 (en) 2018-12-06
EP3632442A1 (en) 2020-04-08
KR102454308B1 (ko) 2022-10-14
AU2020210278A1 (en) 2020-08-20
IL283943B1 (en) 2023-04-01
TWI736135B (zh) 2021-08-11
HUE047719T2 (hu) 2020-05-28
DK2961410T3 (da) 2020-02-17
KR20220143146A (ko) 2022-10-24
US9932341B2 (en) 2018-04-03
IL240784B (en) 2020-06-30
JP7189185B2 (ja) 2022-12-13
KR102717616B1 (ko) 2024-10-16
KR20230145517A (ko) 2023-10-17
PH12015501920B1 (en) 2016-01-18
JP2016510035A (ja) 2016-04-04
MX2015011273A (es) 2015-12-03
ES2945212T3 (es) 2023-06-29
SG10201707130UA (en) 2017-10-30
CR20150472A (es) 2016-01-04
AU2022218495B2 (en) 2024-10-03
AU2024287194A1 (en) 2025-01-23
AU2014223257B2 (en) 2018-11-29
CY1122712T1 (el) 2021-03-12
EP2961410B1 (en) 2019-12-11
IL274771A (en) 2020-07-30
SG11201506654UA (en) 2015-09-29
US20210332059A1 (en) 2021-10-28
EP4233869A3 (en) 2023-11-01
CN105120871B (zh) 2018-08-10
US20220119393A1 (en) 2022-04-21
US20250289823A1 (en) 2025-09-18
AU2018264053B2 (en) 2020-08-20
KR102586858B1 (ko) 2023-10-11
KR102298150B1 (ko) 2021-09-07
EA201591612A1 (ru) 2016-05-31
US20220106318A1 (en) 2022-04-07
JP6776399B2 (ja) 2020-10-28
HRP20200263T1 (hr) 2020-05-29
TW201444846A (zh) 2014-12-01
TW202214254A (zh) 2022-04-16
PH12019501321A1 (en) 2020-10-12
CN105120871A (zh) 2015-12-02
MY177875A (en) 2020-09-24
JP2023036609A (ja) 2023-03-14
RS59958B1 (sr) 2020-03-31
AU2020210278B2 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CL2015002442A1 (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la pi3kd
TWD187330S (zh) 汽車
TWD174059S (zh) 速克達摩托車
TWD163812S (zh) 車輛之頭燈
UY35500A (es) Indazoles sustituidos con heteroarilo
EP3061124A4 (en) Vertical non-planar semiconductor device for system-on-chip (soc) applications
TWD171869S (zh) 速克達摩托車
TWD166111S (zh) 速克達摩托車
PT2956347T (pt) Mesa de passageiro
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
EP3089845A4 (en) Five-axis machining apparatus
TWD180659S (zh) 車輛輪圈蓋(一)
TWD180660S (zh) 車輛輪圈蓋(二)
TWD160618S (zh) 硏磨件
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
HRP20171882T1 (hr) Elektrolitna smjesa za elektrokemijske članke
EP3070716A4 (en) Xy table device
IN2013MU01113A (enExample)
TWD176305S (zh) 長形構件固定用鎖片
TWD173570S (zh) 汽車用頭燈組
MX369174B (es) Proceso para la preparación de un compuesto.
IN2013MU03768A (enExample)
TWD173206S (zh) 汽車用前散熱板
CR20130484A (es) Método para perparar compuestos macrocíclicos inhibidores de serina proteasas de hepatitis c
TWD173207S (zh) 汽車之儀表板